Please assess the completion status of the following clinical trial:

Trial Title: Strain and Blood Inflammatory Markers as Prognostic Tools for ARDS AMIS (ARDS - Markers of Inflammation - Strain)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Moderate to severe ARDS (Berlin Definition)~* Acute beginning \<1 week~* PaO2/FiO2 ratio ≤ 200 after 24h mechanical ventilation with PEEP≥5cmH2O~* Bilateral opacities on chest X-ray~* Respiratory failure not fully explain by cardiac failure or fluid overload~* Informed consent signed by the next of kin and secondarily by the patient when awake~* Patient with social insurance~No Inclusion criteria~* Age \< 18~* Pregnancy a pregnancy test will be done to women of childbearing age~* Chronic obstructive pulmonary disease~* Severe hypoxemia PaO2/FiO2 \<50% with high PEEP~* Immunosuppressive treatment~* Immunodeficiency onco-hematology, HIV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Inflammatory markers (Type: OTHER): All patients with inclusion criteria (ARDS moderate and severe: Berlin definition) and absence of non inclusion criteria will have a broncho alveolar wash at day 0 and blood sample every three day to measure inflammatory markers. All patients will receive protective ventilation with low tidal volume and pressures limited (Pplat \<30cmH2O). End-Expiratory Lung Volume and strain will be measured every 6 hours from the inclusion to the extubation.

Based on this trial design, predict the completion outcome and termination type (if applicable).